Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry
Autor
Ramos-Rincón, José Manuel
Cobos-Palacios, Lidia
López-Sampalo, Almudena
Ricci, Michele
Rubio-Rivas, Manuel
Martos-Pérez, Francisco
Lalueza-Blanco, Antonio
Moragón-Ledesma, Sergio
Fonseca-Aizpuru, Eva-María
García-García, Gema-María
Beato-Pérez, José-Luis
Josa-Laorden, Claudia
Arnalich-Fernández, Francisco
Molinos-Castro, Sonia
Torres‑Peña, J.D.
Artero, Arturo
Vargas-Núñez, Juan-Antonio
Méndez-Bailón, Manuel
Loureiro-Amigo, Jose
Hernández-Garrido, María-Soledad
Peris-García, Jorge
López-Reboiro, Manuel-Lorenzo
Barón-Franco, Bosco
Casas-Rojo, José Manuel
Gómez-Huelgas, Ricardo
SEMI‐COVID‐19 Network
Editor
MDPIFecha
2022Materia
COVID-19SARS-CoV-2
Ethnic groups
Minority groups
Migrants
Spain
METS:
Mostrar el registro METSPREMIS:
Mostrar el registro PREMISMetadatos
Mostrar el registro completo del ítemResumen
This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5–58.9) to 57.1 (44.1–67.1) vs. 71.5 (59.5–81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10–0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17–1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26–2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21–1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.
Fuente
Journal of Clinical Medicine 11(7), 1949 (2022)Versión del Editor
https://doi.org/10.3390/jcm11071949Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
In Vitro Activity of Tedizolid against Mycobacterium tuberculosis
Ruiz Martínez, P.; Causse, Manuel; Vaquero Abellán, Manuel; Casal Román, Manuel (American Society for Microbiology, 2019)Tedizolid is a novel oxazolidinone with activities against Gram-positive microorganisms, including mycobacteria. We studied the in vitro activity of tedizolid against 120 Mycobacterium tuberculosis strains, including ... -
Right Ventricular Function in long-term survivors of childhood acute Lymphoblastic Leukemia: from the CTOXALL study
Heredia, Gloria; González Manzanares, Rafael; Ojeda, Soledad; Molina, Juan Ramón; Fernández-Aviles, Consuelo; Hidalgo, F.; López Aguilera, José; Crespín Crespín, Manuel; Mesa, Dolores; Anguita, Manuel; Castillo, Juan C.; Pan, Manuel (MDPI, 2023)There are limited data regarding right ventricle (RV) impairment in long-term survivors of childhood acute lymphoblastic leukemia (CLS). The aim of this study was to assess RV function in these patients using echocardiographic ... -
Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma
López Cánovas, Juan Luis; Río Moreno, Mercedes del; García Fernández, Helena; Jiménez-Vacas, J.M.; Moreno Montilla, M. Trinidad; Sánchez-Frías, Marina; Amado-Torres, Víctor; L-López, Fernando; Fernández Fondevila, Marcos; Ciria, Rubén; Gómez-Luque, Irene; Briceño Delgado, Francisco Javier; Nogueiras, Rubén; Mata, Manuel de la; Castaño, Justo P.; Rodríguez-Perálvarez, Manuel; Luque, Raúl M.; Gahete Ortiz, Manuel D. (Elsevier, 2020)Splicing alterations represent an actionable cancer hallmark. Splicing factor 3B subunit 1 (SF3B1) is a crucial splicing factor that can be targeted pharmacologically (e.g. pladienolide-B). Here, we show that SF3B1 is ...